Copyright
©The Author(s) 2016.
World J Crit Care Med. Feb 4, 2016; 5(1): 89-95
Published online Feb 4, 2016. doi: 10.5492/wjccm.v5.i1.89
Published online Feb 4, 2016. doi: 10.5492/wjccm.v5.i1.89
Ref. | Study design | Population | Steroid regimen | Outcomes |
Bourdreault et al[33] | Retrospective cohort | 143 hematopoietic cell transplant patients with seasonal influenza | Prednisone < 1 mg/kg per day (low dose) or prednisone > 1 mg/kg per day (high dose) | Steroid use not associated with lower respiratory disease, hypoxemia, need for MV or death |
Brun-Buisson et al[36] | Retrospective cohort | 208 patients with ARDS due to H1N1 pneumonia, 83 receiving steroids | Hydrocortisone 270 mg/d (median) for 11 d (median) | Steroid was associated with mortality in crude analysis (33% vs 18%, HR = 2.4; 95%CI: 1.3-4.3; P = 0.004) and after propensity score-adjusted analysis (HR = 2.82; 95%CI: 1.5-5.4; P = 0.002) |
Early therapy ( ≤ 3 d of MV) associated with increased mortality | ||||
Steroid associated with bacterial pneumonia and prolonged MV | ||||
Confalonieri et al[44] | Case report | One patient with ARDS due to H1N1 infection, not responding to antiviral therapy | Methylprednisolone 1 mg/kg per day | Clinical improvement |
Cornejo et al[40] | Case report | Two patients with H1N1 that developed organizing pneumonia | Methylprednisolone 500 mg/d for 3 d | Clinical improvement |
Diaz et al[37] | Multicenter, prospective cohort | 372 patients with primary H1H1 pandemic pneumonia, 136 receiving steroids | Not reported | Corticosteroid therapy was not significantly associated with mortality (HR = 1.06; 95%CI: 0.626-1.801; P = 0.825) after a regression analysis adjusted for severity and potential confounding factors |
Han et al[45] | Multicenter, retrospective cohort | 83 patients with H1N1 pneumonia with hospitalar admission, 17 with early glucocorticoid treatment | Median dose of methylprednisolone equivalent of 50 mg/d (use for fever reduction) to 61 mg/d (use for pneumonia) | Early steroid treatment (< 72 h) was associated with development of critical disease compared with who received late (> 72 h) or no steroid treatment: 71% vs 39% (HR = 1.8; 95%CI: 1.2-2.8), after adjustment for confounding variables |
Kim et al[35] | Multicenter, retrospective cohort and case-control study | 245 patients with H1N1 infection, 107 with steroid treatment | Median dose of prednisolone equivalent of 75 mg/d | 90-d mortality rate higher in steroids group (OR = 2.2; 95%CI: 1.03-4.71), after propensity score |
Higher mortality both in cohort (58% vs 27%; P < 0.001) and case-control study (54% vs 31%; P = 0.004) | ||||
Steroid group more likely to have secondary bacterial pneumonia, invasive fungal infection and prolonged intensive care unit stay | ||||
Luyt et al[46] | Multicenter, prospective cohort study | 37 survivors of ARDS due to H1N1 infection, 20 with steroid treatment | Not reported | No relationship between steroid use and muscle weakness at 1-yr post-ICU discharge |
Martin-Loeches et al[31] | Multicenter, prospective cohort study | 220 patients with H1N1 infection, 126 with steroid treatment at ICU admission | Minimal equivalent dose of 24 mg/d (methylprednisolone) or 30 mg/d (prednisone) | Early use of steroids was not significantly associated with mortality by Cox regression analysis adjusted for severity and confounding factors: HR = 1.3; 95%CI: 0.7-2.4; P = 0.4 |
Early steroid use associated with an increased rate of HAP (OR = 2.2; 95%CI: 1.0-4.8; P < 0.05) by Cox regression analysis | ||||
Similar results observed when only patiens with ARDS were analyzed | ||||
Patients who received early steroid therapy were sicker than who did not receive them according to SAPS 3 (55.9 ± 16.8 vs 49.0 ± 14.5; P = 0.001) | ||||
Quispe-Laime et al[47] | Case series | 13 patients with suspected H1N1 pneumonia and ALI-ARDS diagnosis | Methylprednisolone 1 mg/kg per day (severe ARDS) or hydrocortisone 300 mg/d. Duration of 21.2 ± 6.1 d | Twelve patients improved lung function, were extubated and discharged alive from the ICU |
By day 7 of treatment patients experienced a significant improvement in lung injury and multiple organ dysfunction scores (P < 0.001) |
- Citation: Nedel WL, Nora DG, Salluh JIF, Lisboa T, Póvoa P. Corticosteroids for severe influenza pneumonia: A critical appraisal. World J Crit Care Med 2016; 5(1): 89-95
- URL: https://www.wjgnet.com/2220-3141/full/v5/i1/89.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v5.i1.89